BioViotica

Actinomycin D

Name: Actinomycin D
Brand: BioViotica
SKU: BVT-0089
Price: 180.00 CHF
Availability: InStock

As low as CHF 60.00

In stock

Only %1 left

BVT-0089-M0055 mgCHF 60.00

BVT-0089-M02525 mgCHF 180.00

BVT-0089-M100100 mgCHF 480.00

Specifications / Handling

More Information
Product Details
Synonyms	Actinomycin IV; Actinomycin C₁; Dactinomycin
Product Type	Chemical
Properties
Formula	C₆₂H₈₆N₁₂O₁₆
MW	1255.4
Merck Index	14: 2800
CAS	50-76-0
RTECS	AU1575000
Source/Host Chemicals	Isolated from Streptomyces parvulus.
Purity Chemicals	≥98% (HPLC)
Appearance	Red shiny crystals.
Solubility	Soluble in DMSO, 100% ethanol or methanol.
Identity	Determined by ¹H-NMR.
Declaration	Manufactured by BioViotica.
Other Product Data	Sensitive to strong acids and bases.
InChi Key	ZOWMRHVAQGTFTG-IZRKADTCSA-N
Smiles	CC(C)[C@@H]1NC(=O)[C@H](NC(=O)C2=CC=C(C)C3=C2N=C2C(O3)=C(C)C(=O)C=C2C(=O)N[C@@H]2[C@H](C)OC(=O)[C@@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]3CCCN3C(=O)[C@@H](NC2=O)C(C)C)[C@H](C)OC(=O)[C@@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]2CCCN2C1=O
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	+4°C
Handling Advice	Keep cool and dry. Protect from light when in solution.
Use/Stability	Stable for at least 1 year after receipt when stored at +4°C. After reconstitution protect from light at -20°C.
Documents
Safety Data Sheet	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Scientific Background Information

Product Description

Antibiotic.
Antitumor compound [2].
Cytotoxic [2].
Apoptosis inducer [1, 2, 6, 7].
RNA synthesis inhibitor [4].
DNA intercalating agent [3, 5].
Mcl-1 expression inhibitor [8]
p53 pathway activator [9].

Product-specific References

Apoptosis induced by Actinomycin D, Camptothecin or Aphidicolin can occur in all phases of the cell cycle: J.M. Glynn, et al.; Biochem. Soc. Trans. 20, 84S (1992)
Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells: J. Kleeff, et al.; Int. J. Cancer 86, 399 (2000)
Influence of DNA base sequence on the binding energetics of actinomycin D: S.A. Bailey, et al.; Biochemistry 32, 5881 (1993)
Effect of actinomycin on RNA synthesis and antibody formation in the anamnestic response in vitro: J.D. Smiley, et al.; J. Exp. Med. 119, 881 (1964)
NMR Solution Structure of a DNA-Actinomycin D Complex Containing a Non-Hydrogen-Bonding Pair in the Binding Site: S.L. Cravens, et al.; J. Am. Chem. Soc. 132, 17588 (2010)
Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes: I. Kalousek, et al.; Anticancer Drugs 18, 763 (2007)
Actinomycin D enhances TRAIL-induced caspase-dependent and -independent apoptosis in SH-SY5Y neuroblastoma cells: M.J. Wang, et al.; Neurosci. Res. 59, 40 (2007)
Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression: K.E. Olberding, et al.; Cancer Biol. Ther. 10, 930 (2010)
Specific activation of the p53 pathway by low dose actinomycin D: M. L. Choong, et al.; Cell Cycle 8, 2810 (2009)
Restoring NAD+ by NAMPT is essential for the SIRT1/p53-mediated survival of UVA- and UVB-irradiated epidermal keratinocytes: T. Katayoshi, et al.; J. Photochem. Photobiol. B 221, 112238 (2021)

Call	+41 61 926 6040
Fax	+41 61 926 6049